• Second Annual Muscle Biology-Focused Research Symposium
• Highlighting Recent Innovations in the Field

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30^th, 2025 from 8:00 AM to 6:00 PM Pacific Time. The event will be held at the Mission Bay Conference Center in San Francisco, CA.

“CLIMB was born out of our vision to bring together key contributors in muscle biology across academia and industry to foster meaningful scientific exchange and showcase novel research,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “As pioneers and leaders in muscle biology, we remain committed to advancing the field by deepening collective understandings underlying muscle-related diseases and disorders.”

CLIMB is an annual one-day research symposium bringing together scientists, researchers and emerging professionals to share innovative research in the field of muscle biology. The symposium seeks to foster collaboration, facilitate networking opportunities and promote interdisciplinary dialogue, with the ultimate goal of driving advancements in the biological understanding and emerging treatment of muscle-related diseases and disorders. CLIMB will feature distinguished expert speakers alongside poster presentations of novel research in the field of muscle biology. Presentations will focus on innovations in cardiac biology, skeletal muscle biology and emerging treatment modalities in muscle biology. Expert speakers include:

• Keynote Speaker: John C. Marioni, Ph.D., Senior Vice President, Head of Computational Sciences, Genentech Research and Early Development
• Craig Blanchette, Ph.D., Senior Vice President, Head of Research, Switch Therapeutics
• Helen Blau, Ph.D., Donald E. and Delia B. Baxter Foundation Professor; Director, Baxter Laboratory for Stem Cell Biology, Stanford University School of Medicine
• Sharlene M. Day, M.D., Presidential Professor and Director of Translational Research, Division of Cardiovascular Medicine and Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine
• W. Michael Flanagan, Ph.D., Chief Scientific Officer, Avidity Biosciences
• Douglas Millay, Ph.D., Professor of Pediatrics, Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati
• Fabio Rossi, M.D., Ph.D., Professor, School of Biomedical Engineering and Department of Medical Genetics, Scientific Director, BC Regenerative Medicine Initiative, University of British Columbia
• Robin M. Shaw, M.D., Ph.D., Director, Nora Eccles Harrison Cardiovascular Research and Training Institute, Professor of Medicine, University of Utah
• Jil C. Tardiff, M.D., Ph.D., Professor of Biomedical Engineering, Medicine, and Cellular and Molecular Medicine, University of Arizona
• Paul Titchenell, Ph.D., Executive Director, Metabolic Physiology, Eli Lilly and Company
  Presenting research completed at the University of Pennsylvania Perelman School of Medicine

To attend CLIMB in person, register online by May 23, 2025, at https://climbsymposium.com/.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology to advance a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements express or implied relating to the properties or potential benefits of aficamten or any of our other drug candidates and our ability to obtain regulatory approval for aficamten for the treatment of obstructive hypertrophic cardiomyopathy or any other indication from FDA or any other regulatory body in the United States or abroad. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757